Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 65 full-time employees. The company went IPO on 2015-06-16. The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.
Follow-Up Questions
Who is the CEO of Healios KK?
Dr. Tadahisa Kagimoto is the President of Healios KK, joining the firm since 2012.
What is the price performance of HLOSF stock?
The current price of HLOSF is $3.5, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Healios KK?
Healios KK belongs to Biotechnology industry and the sector is Health Care
What is Healios KK market cap?
Healios KK's current market cap is $403.9M
Is Healios KK a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Healios KK, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
